一般演題21
血友病製剤臨床試験/New Hemophilia Drugs: Clinical Trials

[O-082] Clinical experience with BIVV001, a new class of factor VIII (FVIII) replacement therapy for hemophilia A

^○Azusa Nagao¹, Barbara A. Konkle², Amy Shapiro³, Doris V. Quon⁴, Janice M. Staber⁵, Roshni Kulkarni⁶, Margaret V. Ragni⁷, Toshko Lissitchkov⁸, Ekta Seth Chhabra⁹, Stacey Poloskey⁹, Stella Lin⁹, Suresh Katragadda⁹, Craig Benson⁹, Annemieke Willemze¹⁰ (1.Ogikubo Hospital, Japan, 2.Bloodworks Northwest and University of Washington, United States of America, 3.Indiana Hemophilia & Thrombosis Center, Inc., United States of America, 4.Orthopaedic Hemophilia Treatment Center, United States of America, 5.University of Iowa, United States of America, 6.Department of Pediatrics and Human Development, Michigan State University, United States of America, 7.Department of Medicine and Hemophilia Center of Western PA, University of Pittsburgh, United States of America, 8.Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Specialized Hospital for Active Treatment of Hematological Diseases, United States of America, 9.Sanofi, United States of America, 10.Sanofi, Netherlands)

Keywords:FVIII